Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has n...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hélène Bugaut, Mélanie Bruchard, Hélène Berger, Valentin Derangère, Ludivine Odoul, Romain Euvrard, Sylvain Ladoire, Fanny Chalmin, Frédérique Végran, Cédric Rébé, Lionel Apetoh, François Ghiringhelli, Grégoire Mignot
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2013
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/86b597f6dd8c41bea39c1cea84b3d20c
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/86b597f6dd8c41bea39c1cea84b3d20c

Documents similaires